AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37865043 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 μg vaccine
Number of subjects: 216
Study 37865043 — intervention group
Group type: EXPERIMENTAL
Intervention: One 45 μg dose of vaccine followed by placebo (Part 1 only)
Number of subjects: 216
Study 37865043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 37865048 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab (NTZ) combined with concurrent chemoradiotherapy (CCRT)
Number of subjects: 56
Study 37865138 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX) 380 mg/month
Number of subjects: 143
Study 37865138 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine-naloxone (BP-NLX) 8-24/2-6 mg daily
Number of subjects: 143
Study 37865138 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 143
Study 37865216 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe postpartum pain (VNS ≥ 8)
Number of subjects: 0
Study 37865216 — intervention group
Group type: EXPERIMENTAL
Intervention: History of depression
Number of subjects: 0
Study 37865216 — intervention group
Group type: EXPERIMENTAL
Intervention: EPDS > 10
Number of subjects: 0
Study 37865216 — intervention group
Group type: EXPERIMENTAL
Intervention: Rooming in with the baby
Number of subjects: 0
Study 37865291 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-122 and miR-21
Number of subjects: 0
Study 37865291 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-144
Number of subjects: 0
Study 37865291 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-mer model
Number of subjects: 0
Study 37865291 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-mer model (adenocarcinoma only)
Number of subjects: 0
Study 37865397 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg) and tremelimumab (75 mg) with neoadjuvant chemotherapy (NAC) for three cycles, followed by interval debulking surgery (IDS), then durvalumab (1120 mg) and adjuvant chemotherapy for three cycles, followed by durvalumab maintenance (1120 mg for total 12 cycles).
Number of subjects: 23
Study 37865397 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) combined with durvalumab and tremelimumab.
Number of subjects: 23
Study 37865397 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events (TRAEs) from durvalumab and tremelimumab.
Number of subjects: 23
Study 37865411 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed problem-solving plus (MAPS+) delivered by community health workers (CHWs)
Number of subjects: 390
Study 37865411 — intervention group
Group type: EXPERIMENTAL
Intervention: Menu of implementation strategies
Number of subjects: 390
Study 37865411 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies for MAPS+
Number of subjects: 390
Study 37865101 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily for 28 days
Number of subjects: 4271
Study 37865101 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 4271
Study 37865101 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 4271
Study 37865418 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine
Number of subjects: 200
Study 37865418 — intervention group
Group type: COMPARATOR
Intervention: 2% mepivacaine
Number of subjects: 200
Study 37865470 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal 15 mg per 0.1 mL pegcetacoplan (monthly)
Number of subjects: 1258
Study 37865470 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal 15 mg per 0.1 mL pegcetacoplan (every other month)
Number of subjects: 1258
Study 37865470 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 1258
Study 37865685 — intervention group
Group type: EXPERIMENTAL
Intervention: RAND-36 questionnaire measuring HRQoL 3-9 months after ICU discharge
Number of subjects: 252
Study 37865685 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 252
Study 37865685 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body mass index
Number of subjects: 252
Study 37865685 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 252
Study 37865685 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 252
Study 37865685 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary illness
Number of subjects: 252
Study 37865685 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric diagnosis
Number of subjects: 252
Study 37865685 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 252
Study 37865685 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated in ICU for COVID-19
Number of subjects: 252
Study 37865736 — intervention group
Group type: EXPERIMENTAL
Intervention: Surf tablet usage
Number of subjects: 32
Study 37865736 — intervention group
Group type: EXPERIMENTAL
Intervention: Surf tablet usage among satisfied parents
Number of subjects: 32
Study 37865736 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth literacy
Number of subjects: 32
Study 37865736 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare satisfaction
Number of subjects: 32
Study 37865752 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum total cholesterol (TC) levels in men aged 45 years or older
Number of subjects: 20544
Study 37865752 — intervention group
Group type: COMPARATOR
Intervention: Serum total cholesterol (TC) levels in women of different ages
Number of subjects: 20544
Study 37865755 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) of the occipital nerves for 12 weeks
Number of subjects: 40
Study 37865755 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst occipital nerve stimulation (ONS) for 12 weeks
Number of subjects: 40
Study 37865755 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic occipital nerve stimulation (ONS) for 12 weeks
Number of subjects: 40
Study 37865755 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS as a preoperative screening tool
Number of subjects: 40
Study 37865755 — intervention group
Group type: COMPARATOR
Intervention: Placebo (deactivated ONS system) for 12 weeks
Number of subjects: 40
Study 37865755 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst ONS
Number of subjects: 40
Study 37865755 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic ONS
Number of subjects: 40
Study 37865755 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in headache pain intensity (numeric rating scale)
Number of subjects: 40
Study 37865755 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in background headache
Number of subjects: 40
Study 37865755 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient's impression of change (PGIC)
Number of subjects: 40
Study 37865755 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (EuroQoL-5D)
Number of subjects: 40
Study 37865755 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sleep quality
Number of subjects: 40
Study 37865755 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of anxiety and depression (Hospital Anxiety and Depression Scale, HADS)
Number of subjects: 40
Study 37865771 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegunigalsidase alfa (1 mg/kg every 2 weeks)
Number of subjects: 20
Study 37865771 — intervention group
Group type: COMPARATOR
Intervention: Agalsidase alfa (0.2 mg/kg every 2 weeks)
Number of subjects: 20
Study 37865776 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ICI collections from patients
Number of subjects: 114
Study 37865776 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ICI collections from patients with irAEs G ≥ 2
Number of subjects: 114
Study 37865776 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment collections from subjects experiencing irAEs G ≥ 2
Number of subjects: 114
Study 37865776 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment collections after steroids
Number of subjects: 114
Study 37865776 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 114
Study 37865777 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing at Intake (MII)
Number of subjects: 150
Study 37865777 — intervention group
Group type: COMPARATOR
Intervention: Standard comprehensive intake assessment (intake-as-usual [IAU])
Number of subjects: 150
Study 37865807 — intervention group
Group type: EXPERIMENTAL
Intervention: COMORAL (multi-channeled oral irrigation unit) used 3 times a day, 5 days a week
Number of subjects: 42
Study 37865807 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementary oral hygiene products, brushing 1-2 times a day)
Number of subjects: 42
Study 37865807 — intervention group
Group type: EXPERIMENTAL
Intervention: COMORAL (multi-channeled oral irrigation unit)
Number of subjects: 42
Study 37865807 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 37865896 — intervention group
Group type: EXPERIMENTAL
Intervention: Lazertinib (240 mg/d)
Number of subjects: 86
Study 37865896 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib (250 mg/d)
Number of subjects: 86
Study 37866094 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular point-of-care tests for infectious disease diagnosis
Number of subjects: 0
Study 37866094 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular point-of-care tests
Number of subjects: 0
Study 37866369 — intervention group
Group type: EXPERIMENTAL
Intervention: Children and Young People's Health Partnership (CYPHP) model of care
Number of subjects: 97970
Study 37866369 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 97970
Study 37866373 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin for 7 days
Number of subjects: 2399
Study 37866373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2399
Study 37866442 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use services that were women-led, safe, and responsive to women's needs
Number of subjects: 36
Study 37866442 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiences of gender-based violence in substance use service settings
Number of subjects: 36
Study 37866442 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle of trauma and drug use exacerbated by oppression in substance use services settings
Number of subjects: 36
Study 37866460 — intervention group
Group type: EXPERIMENTAL
Intervention: Remibrutinib 100 mg twice daily for 52 weeks
Number of subjects: 230
Study 37866669 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (aHSCT) with cyclophosphamide 200 mg/Kg and rituximab 1000 mg
Number of subjects: 21
Study 37867141 — intervention group
Group type: COMPARATOR
Intervention: CASR rs1042636
Number of subjects: 75
Study 37867141 — intervention group
Group type: EXPERIMENTAL
Intervention: IRF2BP1 rs60158447 GC genotype
Number of subjects: 75
Study 37867184 — intervention group
Group type: EXPERIMENTAL
Intervention: Headaches reported at M12
Number of subjects: 277
Study 37867184 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 277
Study 37867184 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing headaches before meningitis
Number of subjects: 277
Study 37867184 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher neutrophilic polynuclei percentage in CSF
Number of subjects: 277
Study 37867184 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain abscess during initial hospitalization
Number of subjects: 277
Study 37867184 — intervention group
Group type: EXPERIMENTAL
Intervention: M12 neuro-functional disability
Number of subjects: 277
Study 37867184 — intervention group
Group type: EXPERIMENTAL
Intervention: M12 physical handicap
Number of subjects: 277
Study 37867184 — intervention group
Group type: EXPERIMENTAL
Intervention: M12 depressive symptoms
Number of subjects: 277
Study 37867184 — intervention group
Group type: EXPERIMENTAL
Intervention: M12 altered physical quality of life
Number of subjects: 277
Study 37867184 — intervention group
Group type: EXPERIMENTAL
Intervention: M12 altered mental quality of life
Number of subjects: 277
Study 37867420 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 704
Study 37867420 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 4 mg/day
Number of subjects: 704
Study 37867420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 704
Study 37867765 — intervention group
Group type: EXPERIMENTAL
Intervention: Good Behavior Game (GBG) training
Number of subjects: 0
Study 37867765 — intervention group
Group type: COMPARATOR
Intervention: Business-as-usual (control)
Number of subjects: 0
Study 37868294 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with a denture brush and chlorhexidine (CHX) toothpaste
Number of subjects: 39
Study 37868294 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacalut cleaning tablet
Number of subjects: 39
Study 37868294 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of brushing and Lacalut cleaning tablet
Number of subjects: 39
Study 37868294 — intervention group
Group type: EXPERIMENTAL
Intervention: Polished acrylic fitting surface
Number of subjects: 39
Study 37868294 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpolished acrylic fitting surface
Number of subjects: 39
Study 37868598 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training and yoga
Number of subjects: 40
Study 37868598 — intervention group
Group type: COMPARATOR
Intervention: Training-as-usual
Number of subjects: 40
Study 37868626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac-derived c-kit+ progenitor cells (CPCs)
Number of subjects: 0
Study 37868626 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC-derived extracellular vesicles (CPC-EV)
Number of subjects: 0
Study 37868649 — intervention group
Group type: EXPERIMENTAL
Intervention: Acthar Gel
Number of subjects: 0
Study 37868649 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0
Study 37868660 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised multicomponent exercise program
Number of subjects: 66
Study 37868660 — intervention group
Group type: COMPARATOR
Intervention: Conventional vestibular rehabilitation at home (control group)
Number of subjects: 66
Study 37868796 — intervention group
Group type: EXPERIMENTAL
Intervention: Faricimab treatment
Number of subjects: 185
Study 37868959 — intervention group
Group type: EXPERIMENTAL
Intervention: CORFU questionnaire
Number of subjects: 148
Study 37868959 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma biomarkers (endothelin-1, von Willebrand factor, Interleukin-1 Receptor antagonist)
Number of subjects: 148
Study 37869030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal lampalizumab 10 mg every 4 weeks (LQ4W)
Number of subjects: 197
Study 37869030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal lampalizumab 10 mg every 6 weeks (LQ6W)
Number of subjects: 197
Study 37869030 — intervention group
Group type: COMPARATOR
Intervention: Sham procedures (pooled)
Number of subjects: 197
Study 37869030 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (LQ4W, LQ6W, pooled sham)
Number of subjects: 197
Study 37869085 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib (80 mg once daily on days 1-21 of each 28 days cycle) + Toripalimab (240 mg, q3w) + High-dose radiotherapy (4-8 fractions of 8-12Gy) and Low-dose radiotherapy (1-10Gy at 0.5-2Gy/fraction)
Number of subjects: 0
Study 37869085 — intervention group
Group type: COMPARATOR
Intervention: Regorafenib (120 mg once daily on days 1-21 of each 28 days cycle)
Number of subjects: 0
Study 37869160 — intervention group
Group type: EXPERIMENTAL
Intervention: AI as a Medical Device (AIaMD) using images taken by iPhone 6S
Number of subjects: 572
Study 37869160 — intervention group
Group type: EXPERIMENTAL
Intervention: AI as a Medical Device (AIaMD) using images taken by Samsung 10
Number of subjects: 572
Study 37869360 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib 400 mg BID
Number of subjects: 0
Study 37869360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37869406 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropilin-1 (NRP-1)
Number of subjects: 0
Study 37869523 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment
Number of subjects: 307
Study 37869881 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 289
Study 37869881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 37869974 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice interactive sleep log
Number of subjects: 17
Study 37869974 — intervention group
Group type: COMPARATOR
Intervention: Paper and pencil logs
Number of subjects: 17
Study 37869974 — intervention group
Group type: COMPARATOR
Intervention: Actigraphy
Number of subjects: 17
Study 37870112 — intervention group
Group type: COMPARATOR
Intervention: recombinant activated factor VII (rFVIIa)
Number of subjects: 4652
Study 37870112 — intervention group
Group type: COMPARATOR
Intervention: antifibrinolytic drugs
Number of subjects: 4652
Study 37870112 — intervention group
Group type: COMPARATOR
Intervention: platelet transfusion
Number of subjects: 4652
Study 37870112 — intervention group
Group type: EXPERIMENTAL
Intervention: prothrombin complex concentrates (PCC)
Number of subjects: 4652
Study 37870130 — intervention group
Group type: COMPARATOR
Intervention: Oral antibiotics (various types including penicillins, cephalosporins, macrolides, and trimethoprim) for 10-14 days
Number of subjects: 2581
Study 37870130 — intervention group
Group type: COMPARATOR
Intervention: Oral antibiotics
Number of subjects: 2581
Study 37870148 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 2266
Study 37870148 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotics
Number of subjects: 2266
Study 37870148 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 2266
Study 37870163 — intervention group
Group type: EXPERIMENTAL
Intervention: SB16 (60 mg dose)
Number of subjects: 168
Study 37870163 — intervention group
Group type: COMPARATOR
Intervention: EU-DEN (60 mg dose)
Number of subjects: 168
Study 37870163 — intervention group
Group type: COMPARATOR
Intervention: US-DEN (60 mg dose)
Number of subjects: 168
Study 37870163 — intervention group
Group type: EXPERIMENTAL
Intervention: SB16, EU-DEN, US-DEN
Number of subjects: 168
Study 37870228 — intervention group
Group type: EXPERIMENTAL
Intervention: PB-IORT (Precision breast intraoperative radiation therapy) with customized CT-based HDR brachytherapy delivering 12.5 Gy to the tumor bed.
Number of subjects: 358
Study 37870228 — intervention group
Group type: EXPERIMENTAL
Intervention: PB-IORT (Precision breast intraoperative radiation therapy) with customized CT-based HDR brachytherapy.
Number of subjects: 358
Study 37870369 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover feet
Number of subjects: 2
Study 37870369 — intervention group
Group type: COMPARATOR
Intervention: Energy-storing feet
Number of subjects: 2
Study 37870510 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonhormonal selective NK3R antagonist
Number of subjects: 0
Study 37870536 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg once every 3 weeks
Number of subjects: 267
Study 37870597 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention website
Number of subjects: 89
Study 37870597 — intervention group
Group type: COMPARATOR
Intervention: Control website
Number of subjects: 89
Study 37870808 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related conversations about healthy eating and physical activity
Number of subjects: 344
Study 37870808 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-related conversations
Number of subjects: 344
Study 37870808 — intervention group
Group type: EXPERIMENTAL
Intervention: Mealtime media use (television/movie watching)
Number of subjects: 344
Study 37870808 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related conversations
Number of subjects: 344
Study 37870836 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH-stimulated AVS
Number of subjects: 228
Study 37870836 — intervention group
Group type: COMPARATOR
Intervention: Non-ACTH-stimulated AVS
Number of subjects: 228
Study 37870862 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (100 mg per day maximum-tolerated dose)
Number of subjects: 132
Study 37870862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 37870862 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (per-protocol analysis)
Number of subjects: 132
Study 37870871 — intervention group
Group type: EXPERIMENTAL
Intervention: mt-sRNA test
Number of subjects: 8920
Study 37870920 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Number of subjects: 266
Study 37870920 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 266
Study 37870947 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal Human Papillomavirus Home Self-Sampling
Number of subjects: 0
Study 37870947 — intervention group
Group type: COMPARATOR
Intervention: Clinician Sampling
Number of subjects: 0
Study 37870949 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus gemcitabine-cisplatin
Number of subjects: 608
Study 37870949 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine-cisplatin alone
Number of subjects: 608
Study 37870954 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tamoxifen citrate, 20 mg/d
Number of subjects: 100
Study 37870954 — intervention group
Group type: COMPARATOR
Intervention: 4-hydroxytamoxifen gel, 2 mg/d per breast
Number of subjects: 100
Study 37870955 — intervention group
Group type: EXPERIMENTAL
Intervention: Tebentafusp
Number of subjects: 0
Study 37870955 — intervention group
Group type: COMPARATOR
Intervention: Control (investigator's choice of therapy with pembrolizumab, ipilimumab, or dacarbazine)
Number of subjects: 0
Study 37870955 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 37870968 — intervention group
Group type: EXPERIMENTAL
Intervention: 960-mg sotorasib-panitumumab
Number of subjects: 0
Study 37870968 — intervention group
Group type: EXPERIMENTAL
Intervention: 240-mg sotorasib-panitumumab
Number of subjects: 0
Study 37870968 — intervention group
Group type: COMPARATOR
Intervention: Standard-care
Number of subjects: 0